Pharmacokinetic Interactions Between Efavirenz and Rifampicin in HIV-Infected Patients with Tuberculosis
作者： Luis F. L??pez-Cort??s , Rosa Ruiz-Valderas , Pompeyo Viciana , Aristides Alarc??n-Gonz??lez , Jes??s G??mez-Mateos
DOI: 10.2165/00003088-200241090-00004
关键词:
摘要: … therapy (HAART) including efavirenz 600mg once daily, on days … efavirenz 600mg once daily (group A-1; n = 8) or efavirenz … on day 8, HAART including efavirenz 800mg once daily was …
springer.com
sci-hub.se 参考文章(16)
Villani, Regazzi, Castelli, Viale, Torti, Seminari, Maserati, Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients British Journal of Clinical Pharmacology. ,vol. 48, pp. 712- 715 ,(1999) , 10.1046/J.1365-2125.1999.00071.X
A.B.M. Jamaluddin, G. Sarwar, M.A. Rahim, M.K. Rahman, High-performance liquid chromatographic assay of rifampicin in human serum Journal of Chromatography B: Biomedical Sciences and Applications. ,vol. 525, pp. 495- 497 ,(1990) , 10.1016/S0378-4347(00)83430-1
Marı́a Sarasa-Nacenta, Yolanda López-Púa, Luis F López-Cortés, Josep Mallolas, José Mª Gatell, Xavier Carné, Determination of efavirenz in human plasma by high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B: Biomedical Sciences and Applications. ,vol. 763, pp. 53- 59 ,(2001) , 10.1016/S0378-4347(01)00357-7
Anton L. Pozniak, Rob Miller, Peter L. Ormerod, The treatment of tuberculosis in HIV-infected persons. AIDS. ,vol. 13, pp. 435- 445 ,(1999) , 10.1097/00002030-199903110-00001
S. M. Gordon, C. R. Horsburgh, C. A. Peloquin, J. A. Havlik, B. Metchock, L. Heifets, J. E. McGowan, S. E. Thompson, Low Serum Levels of Oral Antimycobacterial Agents in Patients with Disseminated Mycobacterium avium Complex Disease The Journal of Infectious Diseases. ,vol. 168, pp. 1559- 1562 ,(1993) , 10.1093/INFDIS/168.6.1559
Jan Sahai, Keith Gallicano, Lori Swick, Sandra Tailor, Gary Garber, Isabelle Seguin, Linda Oliveras, Scott Walker, Anita Rachlis, D William Cameron, Reduced Plasma Concentrations of Antituberculosis Drugs in Patients with HIV Infection Annals of Internal Medicine. ,vol. 127, pp. 289- 293 ,(1997) , 10.7326/0003-4819-127-4-199708150-00006
K Polasa, KJ Murthy, K Krishnaswamy, Rifampicin kinetics in undernutrition. British Journal of Clinical Pharmacology. ,vol. 17, pp. 481- 484 ,(1984) , 10.1111/J.1365-2125.1984.TB02377.X
Catia Marzolini, Amalio Telenti, Laurent A. Decosterd, Gilbert Greub, Jérôme Biollaz, Thierry Buclin, Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. ,vol. 15, pp. 71- 75 ,(2001) , 10.1097/00002030-200101050-00011
Charles A Peloquin, Annette T Nitta, William J Burman, Karen F Brudney, Jorge R Miranda-Massari, Margaret E McGuinness, Shaun E Berning, Gail T Gerena, Low Antituberculosis Drug Concentrations in Patients with AIDS Annals of Pharmacotherapy. ,vol. 30, pp. 919- 925 ,(1996) , 10.1177/106002809603000901
M. T. Kenny, B. Strates, Metabolism and Pharmacokinetics of the Antibiotic Rifampin Drug Metabolism Reviews. ,vol. 12, pp. 159- 218 ,(1981) , 10.3109/03602538109011084